Clinical Trial Update: The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs [Phase 3]

View source ↗

Summary

The trial offers early access to TMC125 (rilpivirine) for HIV-1 infected patients who have failed multiple antiretroviral regimens. It will also collect long-te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Edurant (rilpivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV-1 | Phase 3 | Status: COMPLETED